<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr1665</article-id><article-id pub-id-type="pmid">17397528</article-id><article-id pub-id-type="doi">10.1186/bcr1665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>FGFR1 </italic>amplification in breast carcinomas: a chromogenic <italic>in situ </italic>hybridisation analysis</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Elbauomy Elsheikh</surname><given-names>Somaia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mrxse@nottingham.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Green</surname><given-names>Andrew R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>andrew.green@nottingham.ac.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lambros</surname><given-names>Maryou BK</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Maryou.Lambros@icr.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Turner</surname><given-names>Nicholas C</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Nicholas.Turner@icr.ac.uk</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Grainge</surname><given-names>Matthew J</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>matthew.grainge@nottingham.ac.uk</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Powe</surname><given-names>Des</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Des.Powe@nottingham.ac.uk</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Ellis</surname><given-names>Ian O</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Ian.Ellis@nottingham.ac.uk</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>Reis-Filho</surname><given-names>Jorge S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jorgerf@icr.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Histopathology, School of Molecular Medical Sciences, A Floor, West Block, Queen's Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, NG7 2UH, UK</aff><aff id="I2"><label>2</label>The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK</aff><aff id="I3"><label>3</label>Division of Epidemiology and Public Health, School of Community Health Sciences, Queen's Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, NG7 2UH, UK</aff><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2007</year></pub-date><volume>9</volume><issue>2</issue><fpage>R23</fpage><lpage>R23</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/9/2/R23"/><history><date date-type="received"><day>1</day><month>12</month><year>2006</year></date><date date-type="rev-request"><day>9</day><month>2</month><year>2007</year></date><date date-type="rev-recd"><day>12</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Elsheikh et al., licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Elsheikh et al., licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Elbauomy Elsheikh Somaia mrxse@nottingham.ac.uk </dc:author><dc:title> FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Breast Cancer Research 9(2): R23-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-5411(2007)9:2&#x0003c;R23&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-5411</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The amplicon on 8p11.2 is reported to be found in up to 10% of breast carcinomas. It has been demonstrated recently that this amplicon has four separate cores. The second core encompasses important oncogene candidates, including the fibroblast growth factor receptor 1 (<italic>FGFR1</italic>) gene. Recent studies have demonstrated that specific <italic>FGFR1 </italic>amplification correlates with gene expression and that FGFR1 activity is required for the survival of a <italic>FGFR1 </italic>amplified breast cancer cell line.</p></sec><sec sec-type="methods"><title>Methods</title><p><italic>FGFR1 </italic>amplification was analysed in tissue microarrays comprising a cohort of 880 unselected breast tumours by means of chromogenic <italic>in situ </italic>hybridisation using inhouse-generated <italic>FGFR1</italic>-specific probes. Chromogenic <italic>in situ </italic>hybridisation signals were counted in a minimum 30 morphologically unequivocal neoplastic cells. Amplification was defined as &#x0003e;5 signals per nucleus in more than 50% of cancer cells or when large gene copy clusters were seen.</p></sec><sec><title>Results</title><p><italic>FGFR1 </italic>amplification was observed in 8.7% of the tumours and was significantly more prevalent in patients &#x0003e;50 years of age and in tumours that lacked HER2 expression. No association was found with other histological parameters. Survival analysis revealed <italic>FGFR1 </italic>amplification as an independent prognostic factor for overall survival in the whole cohort. Subgroup analysis demonstrated that the independent prognostic impact of <italic>FGFR1 </italic>amplification was only seen in patients with oestrogen-receptor-positive tumours, where <italic>FGFR1 </italic>amplification was the strongest independent predictor of poor outcome.</p></sec><sec><title>Conclusion</title><p>Given that up to 8.7% of all breast cancers harbour <italic>FGFR1 </italic>amplification and that this amplification is an independent predictor of overall survival, further studies analysing the <italic>FGFR1 </italic>as a potential therapeutic target for breast cancer patients are warranted.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Amplification of 8p11.2-p12 is reported to be found in up to 10&#x02013;15% of all breast cancers [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. For a long time it was believed that the fibroblast growth factor receptor 1 (<italic>FGFR1</italic>) would be the target oncogene of 8p11.2-p12 amplifications [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Recent studies, however, have called into question the role of <italic>FGFR1 </italic>as the 'amplicon driver', given that not all cell lines and breast cancers with 8p11.2-p12 amplification overexpressed the <italic>FGFR1 </italic>gene and that FGFR1 protein and mRNA expression was much more pervasive than gene amplification [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Other oncogene candidates for the amplicon on 8p11.2-p12 have been put forward, including zinc finger protein 703 (<italic>FLJ14299</italic>), SPFH domain family member 2 (<italic>SPFH2</italic>, also known as <italic>C8orf2</italic>), subunit of RNA polymerase III transcription initiation factor (<italic>BRF2</italic>) and RAB11 family interacting protein 1 (<italic>RAB11FIP1</italic>) [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Gelsi-Boyer and colleagues [<xref ref-type="bibr" rid="B3">3</xref>] have demonstrated more recently that the 8p11.2-p12 amplicon is much more complex than previously anticipated and that it comprises at least four independent cores, which can be amplified independently [<xref ref-type="bibr" rid="B3">3</xref>]. While <italic>FLJ14299</italic>, <italic>SPFH2</italic>, proline synthetase cotranscribed homologue (<italic>PROSC</italic>), <italic>BRF2</italic>, and <italic>RAB11FIP1 </italic>were associated with core A1, golgin subfamily a 7 (<italic>GOLGA7</italic>) was correlated with A3, and MYST histone acetyltransferase 3 (<italic>MYST3</italic>) and miR172-resistant version of AP2 (<italic>AP2M3</italic>) were associated with A4. The genes whose expression correlated with amplification of core A2 included LSM1 homologue, U6 small nuclear RNA associated (<italic>LSM1</italic>, also known as cancer-associated Sm-like (<italic>CASM</italic>)), DDHD domain containing 2 (<italic>DDHD2</italic>), phosphatidic acid phosphatase type 2 domain containing 1B (<italic>HTPAP</italic>), Wolf&#x02013;Hirschhorn syndrome candidate 1-like 1 (<italic>WHSC1L1</italic>), <italic>TM2 </italic>and <italic>FGFR1 </italic>[<xref ref-type="bibr" rid="B3">3</xref>]. Interestingly, amplification of core 2, but not the other cores, was associated with shorter metastasis-free survival [<xref ref-type="bibr" rid="B3">3</xref>].</p><p><italic>FGFR1 </italic>gene encodes a tyrosine kinase receptor that is part of the fibroblast growth factor and growth factor receptors family [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. FGFR1 expression has been shown to play pivotal roles in mammary development and breast cancer tumourigenesis [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Activation of FGFR1 in a transgenic mouse model resulted in increased luminal cell proliferation, activation of mitogen-activated protein kinase and Akt, lateral budding and, eventually, alveolar hyperplasia and invasive lesions [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. In addition, we have recently demonstrated that when core 2 of the 8p11.2-p12 is amplified, the <italic>FGFR1 </italic>gene shows increased levels of mRNA and protein expression [<xref ref-type="bibr" rid="B14">14</xref>]. Furthermore, we have also determined <italic>in vitro </italic>that FGFR1 signalling is paramount for the survival of a <italic>FGFR1 </italic>amplified breast cancer cell line [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The prognostic impact of <italic>FGFR1 </italic>amplification in breast cancer still remains unclear. In previous studies analysing <italic>FGFR1 </italic>amplification by means of Southern blot or fluorescent <italic>in situ </italic>hybridisation, conflicting results were observed: while <italic>FGFR1 </italic>amplification proved to be associated with positivity for oestrogen receptor (ER) in one study [<xref ref-type="bibr" rid="B1">1</xref>], Prentice and colleagues found no association between <italic>FGFR1 </italic>amplification and clinicopathological parameters or patients' survival [<xref ref-type="bibr" rid="B4">4</xref>]. More recently, using probes for both <italic>RAB11FIP1 </italic>and <italic>FGFR1</italic>, Letessier and colleagues [<xref ref-type="bibr" rid="B15">15</xref>] demonstrated that cases with 8p12 amplification have a significantly shorter metastasis-free survival [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Chromogenic <italic>in situ </italic>hybridisation (CISH) is a technique that allows for a concurrent analysis of the gene copy number and morphological features of the cells [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Although results obtained with CISH show an excellent concordance with those obtained with fluorescent <italic>in situ </italic>hybridisation [<xref ref-type="bibr" rid="B21">21</xref>], CISH has proven useful for high-throughput copy number assessment, given that it can be easily applied to tissue microarrays and the analysis can be performed with a conventional light microscope [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. No studies analysing <italic>FGFR1 </italic>amplification, as defined by CISH, in a large cohort of breast cancer patients have so far been performed. Using a previously described method [<xref ref-type="bibr" rid="B18">18</xref>], inhouse probes specific for <italic>FGFR1 </italic>were generated and we set out to characterise the prevalence of <italic>FGFR1 </italic>amplification in a large community-based cohort of breast cancers and its correlations with traditional clinicopathological features, immunohistochemical markers, and disease-free and overall survival.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Tissue microarrays</title><p>The tissue microarrays comprised a cohort of 880 unselected breast tumours from patients presenting between 1986 and 1998 entered into the Nottingham Tenovus Primary Breast Carcinoma Series (447 invasive ductal carcinomas of no special type, 183 tubular mixed carcinomas, 25 medullary carcinomas, 84 lobular carcinomas, 28 tubular carcinomas, eight mucinous carcinomas, six cribriform carcinomas, four papillary carcinomas, 29 mixed no special type and lobular carcinomas, 23 mixed no special type and special-type carcinomas, and six miscellaneous tumours &#x02013; histological type not available in 37 cases). Patient management was based on tumour characteristics by the Nottingham Prognostic Index (NPI) and hormone receptor status. Patients with an NPI score &#x02264;3.4 received no adjuvant therapy, and those with a NPI score &#x0003e;3.4 received tamoxifen if they were ER-positive (&#x000b1; Zoladex if premenopausal) or received classical cyclophosphamide, methotrexate and 5-fluorouracil if they were ER-negative and fit enough to tolerate chemotherapy [<xref ref-type="bibr" rid="B22">22</xref>]. Full details of the characterisation of the tissue microarray and the cohort of patients are summarised in Table <xref ref-type="table" rid="T1">1</xref>. Tumours were graded according to a modified Bloom&#x02013;Richardson scoring system [<xref ref-type="bibr" rid="B23">23</xref>] and size was categorised according to the TNM staging criteria [<xref ref-type="bibr" rid="B24">24</xref>]. The NPI was calculated as previously described [<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Survival data including the survival time and the disease-free interval were maintained on a prospective basis. Disease-free survival was defined as the interval (in months) from the date of the primary surgical treatment to the first locoregional (including invasive malignancy and ductal carcinoma <italic>in situ</italic>) or distant recurrence. Overall survival was taken as the time (in months) from the date of the primary surgical treatment to the time of death from breast cancer. The immunohistochemical methods and the results on ER, progesterone receptor, cytokeratin (CK) 7/8, CK 18, CK 19, CK 5/6, CK 14, HER2 and epidermal growth factor receptor have been previously described [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>].</p><p>This study was approved by the Nottingham Research Ethics Committee 2 under the title 'Development of a molecular genetic classification of breast cancer'.</p></sec><sec><title>Chromogenic <italic>in situ </italic>hybridisation</title><p>CISH for <italic>FGFR1 </italic>gene amplification was performed on 2-&#x003bc;m-thick tissue microarray sections mounted on polylysine-coated slides, using an inhouse-generated probe as previously described [<xref ref-type="bibr" rid="B18">18</xref>]. This probe comprises three bacterial artificial chromosome contigs (RP11-350N15, RP11-148D21 and RP11-359P11), which map to the region 38.3&#x02013;38.6 Mb on chromosome 8p12-p11.23 and encompasses the <italic>FGFR1 </italic>and part of <italic>WHSC1L1</italic>. Heat pretreatment of deparaffinised sections consisted of incubation for 15 minutes at 98&#x000b0;C in CISH pretreatment buffer (SPOT-light tissue pretreatment kit; Zymed (South San Francisco, CA, USA) and digestion with pepsin for 5.5 minutes at room temperature according to the manufacturer's instructions. Slides were hybridised and developed as previously described. An appropriate <italic>FGFR1 </italic>gene-amplified breast carcinoma control was included in the slide run.</p><p>CISH experiments were analysed by two of the authors (SEE and ARG) on a multiheaded microscope. Only unequivocal signals were counted. Signals were evaluated at 400 &#x000d7; magnification and 630 &#x000d7; magnification, and 30 morphologically unequivocal neoplastic cells in each core were assessed for the presence of the <italic>FGFR1 </italic>gene signals. Amplification was defined as those cases where &#x0003e;50% of the neoplastic cells harboured either &#x0003e;5 copies of the gene or large gene clusters. CISH analysis was performed with observers blinded to clinicopathological parameters, patients' survival and results of the immunohistochemical analysis.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS 13.0 statistical software (SPSS INC., Chicago, IL, USA). Median follow-up was defined as the median follow-up for those patients still alive and disease free at the latest hospital visit. Cutoff values for the different biomarkers included in this study were chosen before statistical analysis. Standard cutoff values were used for established prognostic factors and were the same as for previously published patient series [<xref ref-type="bibr" rid="B27">27</xref>]. All factors were used as dichotomous covariates in the statistical analysis with the exception of grade and the NPI, which were categorised into three groups.</p><p>The associations between the <italic>FGFR1 </italic>amplification and clinicopathological parameters were evaluated by the chi-square test. Confidence intervals of 95% were adopted. A two-sided <italic>P </italic>value &#x0003c;0.05 was considered statistically significant. Survival curves were calculated by the Kaplan&#x02013;Meier method. Differences in survival on the basis of <italic>FGFR1 </italic>amplification were estimated using the log-rank test. Multivariate Cox regression analysis was used to evaluate any independent prognostic effect of the variable on disease-free survival and the overall survival, which was adjusted by such well-known prognostic factors as tumour grade, lymph node stage, tumour size, and ER status.</p></sec></sec><sec><title>Results</title><p>After excluding the uninformative tissue microarray cores, results on <italic>FGFR1 </italic>amplification were available for 496 tumours. Forty-three tumours (8.7%) showed either &#x0003e;5 signals or large gene clusters in &#x0003e;50% of neoplastic cells (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>Complete clinical follow-up information was available for 478 patients for whom <italic>FGFR1 </italic>CISH results were optimal. The median follow-up period was 58 months (range 1&#x02013;192 months). During this period, a total of 73 (14.7%) patients died from breast cancer. Of all cases, 116 (24.3%) cases were grade 1, 141 (29.5%) cases were grade 2, and 221 (46.2%) were grade 3. From the available data, 153 (32.2%) of the patients had lymph-node-positive disease, 130 (27.8%) had positive vascular invasion, and 311 (65.1%) had tumour size &#x02265;1.5 cm. Recurrence occurred in 147 cases (30.8%), and distant metastases developed in 84 cases (17.6%). A total of 149/496 (30%) patients received tamoxifen, 5/496 (1%) received tamoxifen and Zoladex, and 309/496 (62.3%) received no endocrine treatment. There was no significant difference between the disease-free interval (<italic>P </italic>= 0.761) or overall survival (<italic>P </italic>= 0.225) between those patients that received hormone therapy compared with those patients that did not. A total of 48/496 (9.7%) patients received chemotherapy.</p><p>Table <xref ref-type="table" rid="T2">2</xref> summarises the associations between <italic>FGFR1 </italic>gene amplification and key prognostic and outcome parameters. In brief, patients with positive <italic>FGFR1 </italic>amplification were significantly more likely to be older than 50 years of age (<italic>P </italic>&#x0003c; 0.05) and to develop distant metastasis (<italic>P </italic>&#x0003c; 0.05). <italic>FGFR1 </italic>amplification showed an inverse correlation with HER2 overexpression. A trend for lack of progesterone receptor expression and negativity for basal markers, as defined by Abd El-Rehim and colleagues [<xref ref-type="bibr" rid="B27">27</xref>], was also observed. No associations were found between <italic>FGFR1 </italic>amplification and the grade, lymph-node stage, NPI, expression of ER, low-molecular-weight cytokeratins (CK 7/8, CK 8 and CK 19) or high-molecular-weight cytokeratins (CK 5/6 and CK 14) or basal-like phenotype as defined by Nielsen and colleagues [<xref ref-type="bibr" rid="B28">28</xref>] (that is, ER-negative and HER2-negative, CK 5/6 and/or epidermal growth factor receptor-positive).</p><p>Kaplan&#x02013;Meier survival analysis revealed an association between <italic>FGFR1 </italic>amplification and a shorter overall survival (<italic>P </italic>= 0.01, log-rank test) (Figure <xref ref-type="fig" rid="F2">2a</xref>). A trend for a shorter disease-free survival and <italic>FGFR1 </italic>amplification was found (<italic>P </italic>&#x0003c; 0.07, log-rank test) (Figure <xref ref-type="fig" rid="F2">2b</xref>). On multivariate Cox hazard analysis adjusted for tumour grade, size and lymph node status, for ER status, and for <italic>FGFR1 </italic>amplification, it was found that the <italic>FGFR1 </italic>amplification was a significant predictor of poor overall survival independent of the other known prognostic parameters (<italic>P </italic>&#x0003c; 0.04) (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>Subgroup analysis revealed that <italic>FGFR1 </italic>amplification was an independent prognostic factor for disease-free survival and overall survival only in ER-positive tumours (Figure <xref ref-type="fig" rid="F2">2c,d</xref> and Table <xref ref-type="table" rid="T4">4</xref>). The association between <italic>FGFR1 </italic>amplification and poor outcome was maintained in the group of patients that received endocrine therapy (Figure <xref ref-type="fig" rid="F2">2e,f</xref>). <italic>FGFR1 </italic>amplification in ER-positive disease was the strongest independent risk factor for poor disease-free survival and overall survival, with a greater hazard ratio than high histological grade. Patients with <italic>FGFR1 </italic>amplification in the ER-positive group were significantly more likely to develop distant metastases and were associated with a lack of progesterone receptor expression (<italic>P </italic>&#x0003c; 0.05) (Table <xref ref-type="table" rid="T5">5</xref>). In the cohort of ER-positive tumours, no further associations between <italic>FGFR1 </italic>amplification and other clinicopathological parameters were found. No associations were seen between <italic>FGFR1 </italic>amplification and survival of patients with ER-negative breast cancers.</p></sec><sec><title>Discussion</title><p>In recent years it has been demonstrated that CISH is a useful technique to determine gene copy numbers and gene amplification on formalin-fixed, paraffin-embedded tissue sections [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Unlike fluorescent <italic>in situ </italic>hybridisation, CISH allows a direct comparison between morphological features of neoplastic cells and the presence of gene amplification [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Furthermore, CISH analysis is relatively quick; in the present study, the whole analysis of <italic>FGFR1 </italic>amplification in a cohort of 880 patients took 2 weeks and, although only one tissue microarray core per tumour was analysed, 56% cases rendered optimal results.</p><p>We demonstrate in the present study that <italic>FGFR1 </italic>amplification is found in 8.7% of breast cancers, which is in agreement with previous studies [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Unlike previous studies where <italic>FGFR1 </italic>amplification was determined by Southern blot analysis [<xref ref-type="bibr" rid="B1">1</xref>], our results and those obtained with other <italic>in situ </italic>methods [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B15">15</xref>] did not show any correlation between <italic>FGFR1 </italic>amplification and low histological grade or positivity for ER. On the other hand, our results demonstrate that <italic>FGFR1 </italic>amplification is an independent predictor of poor outcome, especially for patients with ER-positive breast cancers. Interestingly, the impact of <italic>FGFR1 </italic>amplification was stronger on overall survival than disease-free survival (that is, higher hazard ratios on multivariate analysis). This may stem from the fact that locoregional recurrences were included as events for disease-free survival analysis, and that overall survival considered only breast-cancer-related deaths as events. Alternatively, this may reflect the association between <italic>FGFR1 </italic>amplification and the development of distant metastasis (<italic>P </italic>= 0.05) or a shorter survival after the first distant recurrence event.</p><p>Our group [<xref ref-type="bibr" rid="B14">14</xref>] and others [<xref ref-type="bibr" rid="B3">3</xref>] have demonstrated that when <italic>FGFR1 </italic>is specifically amplified (that is, amplification of core A2 of the 8p11.2-p12 amplicon) it is also overexpressed, and that <italic>FGFR1 </italic>signalling is important for the survival of a cell line that harbours <italic>FGFR1 </italic>amplification and high-level gene expression [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Taken together, these results suggest that, in a significant proportion of cases with core A2 amplification, <italic>FGFR1 </italic>may be the actual amplicon driver [<xref ref-type="bibr" rid="B6">6</xref>]. We could not correlate <italic>FGFR1 </italic>amplification with expression in this study, as it was not possible to optimise antibodies for FGFR1 immunohistochemical analysis on tissue microarrays due to the highly fixation-dependent nature of the commercially available antibodies (data not shown).</p><p>The <italic>FGFR1 </italic>gene encodes a tyrosine kinase receptor that has been shown to play an important role in mammary gland development [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Previous studies have shown <italic>in vitro </italic>and <italic>in vivo </italic>that <italic>FGFR1 </italic>overexpression has oncogenic properties [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Furthermore, <italic>FGFR1 </italic>has been implicated in the tumourigenesis of haematological malignancies, where it is frequently involved in balanced chromosomal translocations, including cases of chronic myeloid leukaemia (<italic>BCR</italic>-<italic>FGFR1 </italic>fusion) and the 8p11 myeloproliferative syndrome/stem cell leukaemia&#x02013;lymphoma syndrome, which is characterised by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, the most common being a fusion between <italic>ZNF198 </italic>and <italic>FGFR1 </italic>[<xref ref-type="bibr" rid="B32">32</xref>]. In preclinical models, the PKC412 tyrosine kinase inhibitor has been shown to successfully inhibit the growth of proliferation of <italic>ZNF198</italic>-<italic>FGFR1</italic>-transformed Ba/F3 cells and to prolong the survival of animals with a ZNF198-FGFR1-induced stem cell leukaemia&#x02013;lymphoma syndrome [<xref ref-type="bibr" rid="B33">33</xref>]. Targeting FGFR1 signalling with RNA interference or with the SU5402 FGFR1 tyrosine kinase inhibitor has been shown to decrease cell survival in a breast cancer cell line with <italic>FGFR1 </italic>amplification [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Conclusion</title><p>Taken together, our results demonstrate that <italic>FGFR1 </italic>amplification is found in 8.7% of breast cancers and is an independent predictor of outcome. Although large studies correlating <italic>FGFR1 </italic>amplification with mRNA and protein expression are still needed, the functional data demonstrating that FGFR1 signalling is required for the survival of breast cancer cells harbouring <italic>FGFR1 </italic>amplification [<xref ref-type="bibr" rid="B14">14</xref>], the relatively high prevalence of <italic>FGFR1 </italic>amplification in breast cancer and the independent prognostic information provided by <italic>FGFR1 </italic>amplification status support the idea that this gene may be a useful therapeutic target for a subgroup of breast cancer patients with <italic>FGFR1 </italic>gene amplification [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Abbreviations</title><p>CISH = chromogenic <italic>in situ </italic>hybridisation; CK = cytokeratin; ER = oestrogen receptor; FGFR1 = fibroblast growth factor receptor 1; NPI = Nottingham Prognostic Index.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SEE and ARG analysed the CISH experiments, performed in part the statistical analysis and helped to draft the manuscript. MBKL performed the laboratory work for <italic>FGFR1 </italic>inhouse probe generation and hybridisation to tissue microarrays. NCT participated in the study design, the interpretation of the results and statistical analysis. MJG supervised and reviewed the statistical analysis. DP participated in the interpretation of the results. IOE participated in the study design, data analysis and helped to draft the manuscript. JSR-F conceived the study, designed the probes for <italic>FGFR1</italic>, supervised the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported in part by Breakthrough Breast Cancer. The authors are grateful to Professor Alan Ashworth for his invaluable comments.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Courjal</surname><given-names>F</given-names></name><name><surname>Cuny</surname><given-names>M</given-names></name><name><surname>Simony-Lafontaine</surname><given-names>J</given-names></name><name><surname>Louason</surname><given-names>G</given-names></name><name><surname>Speiser</surname><given-names>P</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name></person-group><article-title>Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>4360</fpage><lpage>4367</lpage><pub-id pub-id-type="pmid">9331099</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuny</surname><given-names>M</given-names></name><name><surname>Kramar</surname><given-names>A</given-names></name><name><surname>Courjal</surname><given-names>F</given-names></name><name><surname>Johannsdottir</surname><given-names>V</given-names></name><name><surname>Iacopetta</surname><given-names>B</given-names></name><name><surname>Fontaine</surname><given-names>H</given-names></name><name><surname>Grenier</surname><given-names>J</given-names></name><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name></person-group><article-title>Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>1077</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">10706127</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelsi-Boyer</surname><given-names>V</given-names></name><name><surname>Orsetti</surname><given-names>B</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Sircoulomb</surname><given-names>F</given-names></name><name><surname>Rouge</surname><given-names>C</given-names></name><name><surname>Lasorsa</surname><given-names>L</given-names></name><name><surname>Letessier</surname><given-names>A</given-names></name><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Monville</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Comprehensive profiling of 8p11-12 amplification in breast cancer</article-title><source>Mol Cancer Res</source><year>2005</year><volume>3</volume><fpage>655</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">16380503</pub-id><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-05-0128</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>LM</given-names></name><name><surname>Shadeo</surname><given-names>A</given-names></name><name><surname>Lestou</surname><given-names>VS</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>deLeeuw</surname><given-names>RJ</given-names></name><name><surname>Makretsov</surname><given-names>N</given-names></name><name><surname>Turbin</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>LA</given-names></name><name><surname>Macpherson</surname><given-names>N</given-names></name><name><surname>Yorida</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="pmid">16027731</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208892</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theillet</surname><given-names>C</given-names></name><name><surname>Adelaide</surname><given-names>J</given-names></name><name><surname>Louason</surname><given-names>G</given-names></name><name><surname>Bonnet-Dorion</surname><given-names>F</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Adnane</surname><given-names>J</given-names></name><name><surname>Longy</surname><given-names>M</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Sismondi</surname><given-names>P</given-names></name><name><surname>Gaudray</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers</article-title><source>Genes Chromosomes Cancer</source><year>1993</year><volume>7</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">7692948</pub-id><pub-id pub-id-type="doi">10.1002/gcc.2870070407</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ugolini</surname><given-names>F</given-names></name><name><surname>Adelaide</surname><given-names>J</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>B</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Pebusque</surname><given-names>MJ</given-names></name></person-group><article-title>Differential expression assay of chromosome arm 8p genes identifies frizzled-related (FRP1/FRZB) and fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>1903</fpage><lpage>1910</lpage><pub-id pub-id-type="pmid">10086345</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1202739</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MJ</given-names></name><name><surname>Pole</surname><given-names>JC</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Teschendorff</surname><given-names>A</given-names></name><name><surname>Naderi</surname><given-names>A</given-names></name><name><surname>Ozdag</surname><given-names>H</given-names></name><name><surname>Vias</surname><given-names>M</given-names></name><name><surname>Kranjac</surname><given-names>T</given-names></name><name><surname>Subkhankulova</surname><given-names>T</given-names></name><name><surname>Paish</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>5235</fpage><lpage>5245</lpage><pub-id pub-id-type="pmid">15897872</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208741</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>ME</given-names></name><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name><name><surname>Washburn</surname><given-names>JG</given-names></name><name><surname>Macoska</surname><given-names>JA</given-names></name><name><surname>Ethier</surname><given-names>SP</given-names></name></person-group><article-title>Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">14729606</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-1022</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Ethier</surname><given-names>SP</given-names></name></person-group><article-title>Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines</article-title><source>Cancer Genet Cytogenet</source><year>2004</year><volume>155</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15527903</pub-id><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.03.013</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><article-title>Cellular signaling by fibroblast growth factor receptors</article-title><source>Cytokine Growth Factor Rev</source><year>2005</year><volume>16</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">15863030</pub-id><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.01.001</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welm</surname><given-names>BE</given-names></name><name><surname>Freeman</surname><given-names>KW</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Contreras</surname><given-names>A</given-names></name><name><surname>Spencer</surname><given-names>DM</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name></person-group><article-title>Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland</article-title><source>J Cell Biol</source><year>2002</year><volume>157</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">12011115</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200107119</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>W</given-names></name><name><surname>Schwertfeger</surname><given-names>KL</given-names></name><name><surname>Vargo-Gogola</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name></person-group><article-title>Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model</article-title><source>J Cell Biol</source><year>2005</year><volume>171</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">16301332</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200505098</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suyama</surname><given-names>K</given-names></name><name><surname>Shapiro</surname><given-names>I</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Hazan</surname><given-names>RB</given-names></name></person-group><article-title>A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor</article-title><source>Cancer Cell</source><year>2002</year><volume>2</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">12398894</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00150-2</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Simpson</surname><given-names>PT</given-names></name><name><surname>Turner</surname><given-names>NC</given-names></name><name><surname>Lambros</surname><given-names>MB</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Grigoriadis</surname><given-names>A</given-names></name><name><surname>Sarrio</surname><given-names>D</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Dexter</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6652</fpage><lpage>6662</lpage><pub-id pub-id-type="pmid">17121884</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1164</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Letessier</surname><given-names>A</given-names></name><name><surname>Sircoulomb</surname><given-names>F</given-names></name><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Monville</surname><given-names>F</given-names></name><name><surname>Gelsi-Boyer</surname><given-names>V</given-names></name><name><surname>Esterni</surname><given-names>B</given-names></name><name><surname>Geneix</surname><given-names>J</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Zemmour</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers</article-title><source>BMC Cancer</source><year>2006</year><volume>6</volume><fpage>245</fpage><pub-id pub-id-type="pmid">17040570</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-6-245</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Pinheiro</surname><given-names>C</given-names></name><name><surname>Lambros</surname><given-names>MB</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Simpson</surname><given-names>PT</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>EGFR amplification and lack of activating mutations in metaplastic breast carcinomas</article-title><source>J Pathol</source><year>2006</year><volume>209</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">16739104</pub-id><pub-id pub-id-type="doi">10.1002/path.2004</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Lambros</surname><given-names>MB</given-names></name><name><surname>James</surname><given-names>M</given-names></name><name><surname>Steele</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>RL</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group><article-title>Cyclin D<sub>1 </sub>protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis</article-title><source>Mod Pathol</source><year>2006</year><volume>19</volume><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">16648863</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3800621</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lambros</surname><given-names>MB</given-names></name><name><surname>Simpson</surname><given-names>PT</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Natrajan</surname><given-names>R</given-names></name><name><surname>Westbury</surname><given-names>C</given-names></name><name><surname>Steele</surname><given-names>D</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>FC</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent <italic>in situ</italic> hybridization</article-title><source>Lab Invest</source><year>2006</year><volume>86</volume><fpage>398</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">16446704</pub-id><pub-id pub-id-type="doi">10.1038/labinvest.3700390</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Gancberg</surname><given-names>D</given-names></name><name><surname>Di Leo</surname><given-names>A</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Rouas</surname><given-names>G</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name></person-group><article-title>Chromogenic <italic>in situ</italic> hybridization: a practical alternative for fluorescence <italic>in situ</italic> hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>1467</fpage><lpage>1472</lpage><pub-id pub-id-type="pmid">11073807</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Chromogenic <italic>in situ</italic> hybridization in tumor pathology</article-title><source>Methods Mol Med</source><year>2004</year><volume>97</volume><fpage>133</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">15064490</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Forsyth</surname><given-names>A</given-names></name><name><surname>Cooke</surname><given-names>TG</given-names></name><name><surname>Watters</surname><given-names>AD</given-names></name><name><surname>Bartlett</surname><given-names>JM</given-names></name></person-group><article-title>Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence <italic>in situ</italic> hybridization</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>4793</fpage><lpage>4798</lpage><pub-id pub-id-type="pmid">15269154</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0428-03</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madjd</surname><given-names>Z</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Paish</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Durrant</surname><given-names>LG</given-names></name></person-group><article-title>Loss of CD59 expression in breast tumours correlates with poor survival</article-title><source>J Pathol</source><year>2003</year><volume>200</volume><fpage>633</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">12898600</pub-id><pub-id pub-id-type="doi">10.1002/path.1357</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up</article-title><source>Histopathology</source><year>1991</year><volume>19</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">1757079</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2559.1991.tb00229.x</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singletary</surname><given-names>SE</given-names></name><name><surname>Connolly</surname><given-names>JL</given-names></name></person-group><article-title>Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual</article-title><source>CA Cancer J Clin</source><year>2006</year><volume>56</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">16449185</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>MH</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Elston</surname><given-names>CE</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>The Nottingham Prognostic Index in primary breast cancer</article-title><source>Breast Cancer Res Treat</source><year>1992</year><volume>22</volume><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">1391987</pub-id><pub-id pub-id-type="doi">10.1007/BF01840834</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Rehim</surname><given-names>DM</given-names></name><name><surname>Ball</surname><given-names>G</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Rakha</surname><given-names>EA</given-names></name><name><surname>Paish</surname><given-names>C</given-names></name><name><surname>Robertson</surname><given-names>JFR</given-names></name><name><surname>MacMillan</surname><given-names>D</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>High throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses</article-title><source>Int J Cancer</source><year>2005</year><volume>116</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">15818618</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21004</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Rehim</surname><given-names>DM</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Paish</surname><given-names>CE</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Expression of luminal and basal cytokeratins in human breast carcinoma</article-title><source>J Pathol</source><year>2004</year><volume>203</volume><fpage>661</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">15141381</pub-id><pub-id pub-id-type="doi">10.1002/path.1559</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Hsu</surname><given-names>FD</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Cheang</surname><given-names>M</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Dressler</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5367</fpage><lpage>5374</lpage><pub-id pub-id-type="pmid">15328174</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0220</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>S</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name></person-group><article-title>CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei</article-title><source>Genes Chromosomes Cancer</source><year>1998</year><volume>22</volume><fpage>268</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">9669664</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199808)22:4&#x0003c;268::AID-GCC2&#x0003e;3.0.CO;2-T</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLeskey</surname><given-names>SW</given-names></name><name><surname>Ding</surname><given-names>IY</given-names></name><name><surname>Lippman</surname><given-names>ME</given-names></name><name><surname>Kern</surname><given-names>FG</given-names></name></person-group><article-title>MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">7506125</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coumoul</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><article-title>Roles of FGF receptors in mammalian development and congenital diseases</article-title><source>Birth Defects Res C Embryo Today</source><year>2003</year><volume>69</volume><fpage>286</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">14745970</pub-id><pub-id pub-id-type="doi">10.1002/bdrc.10025</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roumiantsev</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Neumann</surname><given-names>CA</given-names></name><name><surname>Dimitri</surname><given-names>CA</given-names></name><name><surname>Asiedu</surname><given-names>F</given-names></name><name><surname>Cross</surname><given-names>NC</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><article-title>Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations</article-title><source>Cancer Cell</source><year>2004</year><volume>5</volume><fpage>287</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">15050920</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(04)00053-4</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Deangelo</surname><given-names>DJ</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Williams</surname><given-names>IR</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Duclos</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Adelsperger</surname><given-names>J</given-names></name><name><surname>Okabe</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>14479</fpage><lpage>14484</lpage><pub-id pub-id-type="pmid">15448205</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0404438101</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p><italic>FGFR1 </italic>gene amplification in breast cancer. <bold>(a) </bold>Grade 3 invasive ductal carcinoma (haematoxylin and eosin; original magnification &#x000d7; 200) with <bold>(b) </bold>one or two copies of FGFR1 (original magnification &#x000d7; 400; inset: &#x000d7; 630). <bold>(c) </bold>Grade 3 invasive ductal carcinoma (haematoxylin and eosin; original magnification &#x000d7; 200) harbouring <bold>(d) </bold><italic>FGFR1 </italic>gene amplification (original magnification &#x000d7; 400; inset: &#x000d7; 630).</p></caption><graphic xlink:href="bcr1665-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Univariate analysis of the prognostic impact of <italic>FGFR1 </italic>gene amplification overexpression on disease-free survival and overall survival. <bold>(a) </bold>Whole cohort, disease-free survival. <bold>(b) </bold>Whole cohort, overall survival. <bold>(c) </bold>Oestrogen-receptor-positive cases, disease-free survival. <bold>(d) </bold>Oestrogen-receptor-positive cases, overall survival. <bold>(e) </bold>Oestrogen-receptor-positive patients that received endocrine therapy, disease-free survival. <bold>(f) </bold>Oestrogen-receptor-positive patients that received endocrine therapy, overall survival.</p></caption><graphic xlink:href="bcr1665-2"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Frequencies and percentages of tumour grades, size, lymph node stage, distant metastasis and patient age in the tissue microarrays</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Frequency</td><td align="left">Percentage</td></tr></thead><tbody><tr><td align="left">Grade</td><td></td><td></td></tr><tr><td align="left">&#x02003;1</td><td align="left">191</td><td align="left">22.7</td></tr><tr><td align="left">&#x02003;2</td><td align="left">273</td><td align="left">32.4</td></tr><tr><td align="left">&#x02003;3</td><td align="left">378</td><td align="left">44.9</td></tr><tr><td align="left">Lymph node stage</td><td></td><td></td></tr><tr><td align="left">&#x02003;0</td><td align="left">561</td><td align="left">66.7</td></tr><tr><td align="left">&#x02003;N1</td><td align="left">203</td><td align="left">24.1</td></tr><tr><td align="left">&#x02003;N2</td><td align="left">77</td><td align="left">9.2</td></tr><tr><td align="left">Tumour size</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02264;1.5 cm</td><td align="left">301</td><td align="left">35.7</td></tr><tr><td align="left">&#x02003;&#x0003e;1.5 cm</td><td align="left">543</td><td align="left">64.3</td></tr><tr><td align="left">Distance metastasis</td><td></td><td></td></tr><tr><td align="left">&#x02003;M0</td><td align="left">717</td><td align="left">85.0</td></tr><tr><td align="left">&#x02003;M1</td><td align="left">127</td><td align="left">15.0</td></tr><tr><td align="left">Age</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02264;50 years</td><td align="left">299</td><td align="left">35.4</td></tr><tr><td align="left">&#x02003;&#x0003e;50 years</td><td align="left">545</td><td align="left">64.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Correlation between <italic>FGFR1 </italic>gene amplification and the clinicopathological variables</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="left">Number of samples</td><td align="left">Positive FGFR1 amplification number (%)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Age</td><td align="left">478</td><td></td><td align="left">0.027</td></tr><tr><td align="left">&#x02003;&#x0003c;50 years</td><td align="left">152</td><td align="left">7 (4.6)</td><td></td></tr><tr><td align="left">&#x02003;&#x02265;50 years</td><td align="left">346</td><td align="left">35 (10.1)</td><td></td></tr><tr><td align="left">Grade</td><td align="left">478</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;1</td><td align="left">116</td><td align="left">10 (8.6)</td><td></td></tr><tr><td align="left">&#x02003;2</td><td align="left">141</td><td align="left">12 (8.5)</td><td></td></tr><tr><td align="left">&#x02003;3</td><td align="left">221</td><td align="left">20 (9.0)</td><td></td></tr><tr><td align="left">Size</td><td align="left">478</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;&#x02265;1.5 cm</td><td align="left">311</td><td align="left">30 (9.6)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;1.5 cm</td><td align="left">167</td><td align="left">12 (7.2)</td><td></td></tr><tr><td align="left">Lymph node stage</td><td align="left">475</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;N0</td><td align="left">322</td><td align="left">28 (8.7)</td><td></td></tr><tr><td align="left">&#x02003;N1</td><td align="left">110</td><td align="left">9 (8.2)</td><td></td></tr><tr><td align="left">&#x02003;N2</td><td align="left">43</td><td align="left">4 (9.3)</td><td></td></tr><tr><td align="left">Nottingham Prognostic Index</td><td align="left">475</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Good</td><td align="left">175</td><td align="left">14 (8.0)</td><td></td></tr><tr><td align="left">&#x02003;Moderate</td><td align="left">239</td><td align="left">21 (8.8)</td><td></td></tr><tr><td align="left">&#x02003;Poor</td><td align="left">61</td><td align="left">6 (9.8)</td><td></td></tr><tr><td align="left">Distant metastasis</td><td align="left">478</td><td></td><td align="left">0.050</td></tr><tr><td align="left">&#x02003;No</td><td align="left">394</td><td align="left">30 (7.6)</td><td></td></tr><tr><td align="left">&#x02003;Definite</td><td align="left">84</td><td align="left">12 (14.3)</td><td></td></tr><tr><td align="left">Vascular invasion</td><td align="left">467</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;No</td><td align="left">337</td><td align="left">27 (8.0)</td><td></td></tr><tr><td align="left">&#x02003;Yes</td><td align="left">130</td><td align="left">14 (10.8)</td><td></td></tr><tr><td align="left">Oestrogen receptor</td><td align="left">453</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">140</td><td align="left">10 (7.1)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">313</td><td align="left">27 (8.6)</td><td></td></tr><tr><td align="left">Progesterone receptor</td><td align="left">449</td><td></td><td align="left">0.084</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">206</td><td align="left">22 (10.7)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">243</td><td align="left">15 (6.2)</td><td></td></tr><tr><td align="left">HER2</td><td align="left">445</td><td></td><td align="left">0.043</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">259</td><td align="left">28 (10.8)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">186</td><td align="left">10 (5.4)</td><td></td></tr><tr><td align="left">Androgen receptor</td><td align="left">415</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">188</td><td align="left">18 (9.6)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">227</td><td align="left">13 (5.7)</td><td></td></tr><tr><td align="left">Cytokeratin 7/8</td><td align="left">467</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">167</td><td align="left">17 (10.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">300</td><td align="left">24 (8.0)</td><td></td></tr><tr><td align="left">Cytokeratin 18</td><td align="left">396</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">116</td><td align="left">7 (6.0)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">280</td><td align="left">23 (8.2)</td><td></td></tr><tr><td align="left">Cytokeratin 19</td><td align="left">464</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">95</td><td align="left">10 (10.5)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">369</td><td align="left">30 (8.1)</td><td></td></tr><tr><td align="left">Cytokeratin 5/6</td><td align="left">465</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">350</td><td align="left">34 (9.7)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">115</td><td align="left">6 (5.2)</td><td></td></tr><tr><td align="left">Cytokeratin 14</td><td align="left">458</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">357</td><td align="left">33 (9.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">101</td><td align="left">6 (5.9)</td><td></td></tr><tr><td align="left">Epidermal growth factor receptor</td><td align="left">351</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">292</td><td align="left">26 (8.9)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">59</td><td align="left">3 (5.1)</td><td></td></tr><tr><td align="left">Basal markers [27]</td><td align="left">455</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">311</td><td align="left">31 (10.0)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">144</td><td align="left">8 (5.6)</td><td></td></tr><tr><td align="left">Nielsen groups [28]</td><td align="left">396</td><td></td><td align="left">Not significant</td></tr><tr><td align="left">&#x02003;HER2</td><td align="left">39</td><td align="left">3 (7.7)</td><td></td></tr><tr><td align="left">&#x02003;Basal-like</td><td align="left">55</td><td align="left">3 (5.5)</td><td></td></tr><tr><td align="left">&#x02003;Luminal</td><td align="left">302</td><td align="left">26 (8.6)</td><td></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Cox proportional hazards analysis for predictors of overall survival: effects of tumour grade, size, lymph node stage, oestrogen receptor status and <italic>FGFR1 </italic>amplification</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left">Hazard ratio</td><td align="left">95% confidence interval</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Grade<sup>a</sup></td><td align="left">2.13</td><td align="left">1.32&#x02013;3.44</td><td align="left">0.002</td></tr><tr><td align="left">Tumour size &#x02265;1.5 cm<sup>b</sup></td><td align="left">2.17</td><td align="left">1.06&#x02013;4.44</td><td align="left">0.034</td></tr><tr><td align="left">Positive lymph node stage</td><td align="left">3.52</td><td align="left">2.17&#x02013;5.72</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Positive oestrogen receptor status</td><td align="left">0.44</td><td align="left">0.26&#x02013;0.74</td><td align="left">0.002</td></tr><tr><td align="left">FGFR1 amplification</td><td align="left">2.00</td><td align="left">1.02&#x02013;3.92</td><td align="left">0.043</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Fitted as a linear term; that is, an increase in risk for change in grade of one unit.</p><p><sup>b</sup>Compared with tumour size &#x0003c;1.5 cm.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Cox proportional hazards analysis for predictors of disease-free and overall survival: effects of tumour grade, size, lymph node stage, oestrogen receptor (ER) status and FGFR1 status in ER-positive and ER-negative tumours</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="center" colspan="3">ER-positive tumours</td><td align="center" colspan="3">ER-negative tumours</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center">Hazard ratio</td><td align="center">95% confidence interval</td><td align="center"><italic>P </italic>value</td><td align="center">Hazard ratio</td><td align="center">95% confidence interval</td><td align="center"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Disease-free interval</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Grade<sup>a</sup></td><td align="center">1.387</td><td align="center">1.027&#x02013;1.874</td><td align="center">0.033</td><td align="center">1.001</td><td align="center">0.637&#x02013;1.574</td><td align="center">0.996</td></tr><tr><td align="left">&#x02003;Tumour size &#x02265;1.5 cm<sup>b</sup></td><td align="center">1.551</td><td align="center">0.926&#x02013;2.595</td><td align="center">0.095</td><td align="center">2.348</td><td align="center">1.092&#x02013;5.052</td><td align="center">0.029</td></tr><tr><td align="left">&#x02003;Positive lymph node stage</td><td align="center">1.407</td><td align="center">0.879&#x02013;2.252</td><td align="center">0.155</td><td align="center">2.597</td><td align="center">1.563&#x02013;4.315</td><td align="center">0.000</td></tr><tr><td align="left">&#x02003;FGFR1 amplification</td><td align="center">2.250</td><td align="center">1.184&#x02013;4.274</td><td align="center">0.013</td><td align="center">1.104</td><td align="center">0.440&#x02013;2.774</td><td align="center">0.833</td></tr><tr><td align="left">Overall survival</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Grade<sup>a</sup></td><td align="center">2.600</td><td align="center">1.471&#x02013;4.594</td><td align="center">0.001</td><td align="center">1.673</td><td align="center">0.731&#x02013;3.829</td><td align="center">0.223</td></tr><tr><td align="left">&#x02003;Tumour size &#x02265;1.5 cm<sup>b</sup></td><td align="center">2.124</td><td align="center">0.792&#x02013;5.697</td><td align="center">0.134</td><td align="center">2.594</td><td align="center">0.911&#x02013;7.387</td><td align="center">0.074</td></tr><tr><td align="left">&#x02003;Positive lymph node stage</td><td align="center">1.973</td><td align="center">0.953&#x02013;4.083</td><td align="center">0.067</td><td align="center">5.124</td><td align="center">2.646&#x02013;9.924</td><td align="center">0.000</td></tr><tr><td align="left">&#x02003;FGFR1 amplification</td><td align="center">3.389</td><td align="center">1.374&#x02013;8.358</td><td align="center">0.008</td><td align="center">1.278</td><td align="center">0.450&#x02013;3.624</td><td align="center">0.645</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Fitted as a linear term; that is, an increase in risk for change in grade of one unit.</p><p><sup>b</sup>Compared with tumour size &#x0003c;1.5 cm.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Correlation between <italic>FGFR1 </italic>gene amplification and the clinicopathological variables in the oestrogen-receptor-positive group</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="center">Number of samples</td><td align="center">Positive FGFR1 amplification number (%)</td><td align="center"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Age</td><td align="center">313</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;&#x0003c;50 years</td><td align="center">95</td><td align="center">6 (6.3)</td><td></td></tr><tr><td align="left">&#x02003;&#x02265;50 years</td><td align="center">218</td><td align="center">21 (9.6)</td><td></td></tr><tr><td align="left">Grade</td><td align="center">313</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;1</td><td align="center">99</td><td align="center">8 (8.1)</td><td></td></tr><tr><td align="left">&#x02003;2</td><td align="center">120</td><td align="center">10 (8.3)</td><td></td></tr><tr><td align="left">&#x02003;3</td><td align="center">94</td><td align="center">9 (9.6)</td><td></td></tr><tr><td align="left">Size</td><td align="center">313</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;&#x02265;1.5 cm</td><td align="center">188</td><td align="center">19 (10.1)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;1.5 cm</td><td align="center">125</td><td align="center">8 (6.4)</td><td></td></tr><tr><td align="left">Lymph node stage</td><td align="center">311</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;N0</td><td align="center">214</td><td align="center">19 (8.9)</td><td></td></tr><tr><td align="left">&#x02003;N1</td><td align="center">74</td><td align="center">6 (8.2)</td><td></td></tr><tr><td align="left">&#x02003;N2</td><td align="center">23</td><td align="center">2 (9.3)</td><td></td></tr><tr><td align="left">Nottingham Prognostic Index</td><td align="center">311</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Good</td><td align="center">148</td><td align="center">11 (7.4)</td><td></td></tr><tr><td align="left">&#x02003;Moderate</td><td align="center">133</td><td align="center">14 (10.5)</td><td></td></tr><tr><td align="left">&#x02003;Poor</td><td align="center">30</td><td align="center">2 (6.7)</td><td></td></tr><tr><td align="left">Distant metastasis</td><td align="center">313</td><td></td><td align="center">0.032</td></tr><tr><td align="left">&#x02003;No</td><td align="center">273</td><td align="center">20 (7.3)</td><td></td></tr><tr><td align="left">&#x02003;Definite</td><td align="center">40</td><td align="center">7 (17.5)</td><td></td></tr><tr><td align="left">Vascular invasion</td><td align="center">303</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;No</td><td align="center">224</td><td align="center">18 (8)</td><td></td></tr><tr><td align="left">&#x02003;Yes</td><td align="center">79</td><td align="center">8 (10.1)</td><td></td></tr><tr><td align="left">Progesterone receptor</td><td align="center">305</td><td></td><td align="center">0.05</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">80</td><td align="center">11 (13.8)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">225</td><td align="center">15 (6.7)</td><td></td></tr><tr><td align="left">HER2</td><td align="center">299</td><td></td><td align="center">0.063</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">179</td><td align="center">20 (11.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">120</td><td align="center">6 (5.0)</td><td></td></tr><tr><td align="left">Androgen receptor</td><td align="center">283</td><td></td><td align="center">0.08</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">90</td><td align="center">11 (12.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">193</td><td align="center">12 (6.2)</td><td></td></tr><tr><td align="left">Cytokeratin 7/8</td><td align="center">310</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">73</td><td align="center">8 (11)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">237</td><td align="center">19 (8.0)</td><td></td></tr><tr><td align="left">Cytokeratin 18</td><td align="center">269</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">46</td><td align="center">1 (2.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">223</td><td align="center">21 (9.4)</td><td></td></tr><tr><td align="left">Cytokeratin 19</td><td align="center">308</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">33</td><td align="center">4 (12.1)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">275</td><td align="center">22 (8.0)</td><td></td></tr><tr><td align="left">Cytokeratin 5/6</td><td align="center">306</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">261</td><td align="center">24 (9.2)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">45</td><td align="center">2 (4.4)</td><td></td></tr><tr><td align="left">Cytokeratin 14</td><td align="center">299</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">252</td><td align="center">23 (9.1)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">47</td><td align="center">2 (4.3)</td><td></td></tr><tr><td align="left">Epidermal growth factor receptor</td><td align="center">242</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">209</td><td align="center">19 (9.1)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">33</td><td align="center">2 (6.1)</td><td></td></tr><tr><td align="left">Basal markers [27]</td><td align="center">297</td><td></td><td align="center">Not significant</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">234</td><td align="center">22 (9.4)</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">63</td><td align="center">3 (4.8)</td><td></td></tr></tbody></table></table-wrap></sec></back></article> 